Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04111172 |
Title用于治疗胃肠道腺癌的疫苗（Ad5.F35-hGCC-PADRE） | 阶段
第二阶段
|
Date Added 2019-10-01 |
地点
Pennsylvania, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
腺病毒 5/F35-人鸟苷酸环化酶 C-PADRE |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03547999 |
TitleA Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | 阶段
第二阶段
|
Date Added 2018-06-06 |
地点
California, United States
Florida, United States Kansas, United States New Jersey, United States Ohio, United States Oregon, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FPV-CV301, mFOLFOX6, MVA-BN-CV301, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03673787 |
Title伊帕塞替联合阿特珠单抗的试验 | 阶段
第 1 阶段
|
Date Added 2018-09-17 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Atezolizumab, Ipatasertib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03990233 |
Title晚期实体瘤患者BI 765063单药治疗及与BI 754091联合治疗试验 | 阶段
第 1 阶段
|
Date Added 2019-06-18 |
地点
比利时
法国 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 754091, BI 765063 |
标签
MSS/ MMRp
|
| NCT ID NCT04973163 |
Title测试不同剂量的 BI 1823911 单独或与其他药物联合用于不同类型的 KRAS 基因突变晚期癌症患者的研究 | 阶段
第 1 阶段
|
Date Added 2021-07-22 |
地点
Texas, United States
比利时 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 1701963, BI 1823911, Midazolam |
标签
MSS/ MMRp
|
| NCT ID NCT04111458 |
TitleA Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | 阶段
第 1 阶段
|
Date Added 2019-10-01 |
地点
Massachusetts, United States
North Carolina, United States Tennessee, United States Texas, United States 德国 荷兰 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 1701963, Trametinib |
标签
MSS/ MMRp
|
| NCT ID NCT05487235 |
TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-08-04 |
地点
阿根廷
澳大利亚 巴西 加拿大 大韩民国 新西兰 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Atezolizumab, GDC-1971, Omeprazole |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03530397 |
Title在晚期实体瘤受试者中评估 MEDI5752 的研究 | 阶段
第 1 阶段
|
Date Added 2018-05-21 |
地点
Michigan, United States
New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States 澳大利亚 法国 意大利 大韩民国 荷兰 葡萄牙 西班牙 台湾 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05879822 |
Title评估INCB099280对免疫检查点抑制剂无效的特定实体瘤患者的作用的研究 | 阶段
第二阶段
|
Date Added 2023-05-30 |
地点
巴西
中国 格鲁吉亚 希腊 Hungary 新西兰 Romania 南非 Turkey |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
INCB099280 |
标签
MSI-H/ MMRd
|
| NCT ID NCT06322693 |
TitleA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | 阶段
第 1 阶段
|
Date Added 2024-03-21 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 大韩民国 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
